What are the pathophysiological consequences of endosomal/lysosomal changes in sporadic AD?

The abstract explicitly states that while endosomal/lysosomal alterations are among the earliest pathological changes in sporadic AD, their pathophysiological consequences are currently unknown. Understanding these consequences is critical for determining whether these changes are causative or merely correlative in AD progression.

Gap type: open_question Source paper: Aberrant sphingomyelin/ceramide metabolic-induced neuronal endosomal/lysosomal dysfunction: potential pathological consequences in age-related neurodegeneration. (2003, Advanced drug delivery reviews, PMID:14597144)

Resolved when an evidence artifact establishes the pathophysiological consequences of endosomal/lysosomal changes in sporadic AD, with one of: (1) functional studies in sporadic AD patient-derived neurons or brain tissue, showing that endosomal/lysosomal dysfunction (enlarged early endosomes by EM, impaired lysosomal acidification by LysoSensor) causes specific downstream pathologies — defective Aβ degradation (>=40% reduced Aβ42 clearance in conditioned media), impaired autophagy flux (LC3-II turnover assay), or mitophagy defects (TMRM mitochondrial potential) — with n >= 4 patient lines; (2) proteomics or lipidomics of isolated endosomal/lysosomal fractions from sporadic AD brain tissue, identifying the specific molecular changes (sphingolipid accumulation, altered v-ATPase subunit composition, reduced cathepsin activity) that distinguish sporadic from familial AD; (3) targeted intervention studies restoring endosomal/lysosomal function (v-ATPase modulators, cathepsin activators, or autophagy inducers) in sporadic AD models, demonstrating >=30% improvement in Aβ clearance, tau pathology, or cognitive endpoints.